Skip to main content

Table 2 Change from baseline in other blood pressure parameters at Week 26

From: Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

  Placebo (n = 504) Ertugliflozin 5 mg (n = 519) Ertugliflozin 15 mg (n = 510)
Pulse pressure, mmHga
 Baseline mean (SD)b 51.8 (12.1) 52.5 (11.3) 52.1 (11.2)
 LS mean change from baseline (95% CI) − 0.8 (− 1.7, 0.0) − 2.7 (− 3.5, − 1.9) − 2.9 (− 3.8, − 2.1)
 Placebo-adjusted LS mean change from baseline (95% CI) − 1.9 (− 3.0, − 0.8) − 2.1 (− 3.3, − 1.0)
Mean arterial pressure, mmHga
 Baseline mean (SD)b 95.2 (8.7) 96.0 (8.5) 95.8 (8.1)
 LS mean change from baseline (95% CI) − 0.3 (− 1.0, 0.4) − 2.8 (− 3.4, − 2.1) − 2.65 (− 3.3, − 2.0)
 Placebo-adjusted LS mean change from baseline (95% CI) − 2.4 (− 3.4, − 1.5) − 2.3 (− 3.2, − 1.4)
Double product, mmHg × bpma
 Baseline mean (SD)c 9409.2 (1536.9) 9544.7 (1668.6) 9480.5 (1571.1)
 LS mean change from baseline (95% CI) − 44.0 (− 161.7, 73.7) − 479.9 (− 594.5, − 365.3) − 514.1 (− 630.8, − 397.4)
 Placebo-adjusted LS mean change from baseline (95% CI) − 435.9 (− 593.6, − 278.2) − 470.0 (− 629.3, − 310.8)
  1. bpm beats per minute, CI confidence interval, LS least squares
  2. aNumber of patients with data at Week 26: 497 (placebo), 506 (ertugliflozin 5 mg), 495 (ertugliflozin 15 mg)
  3. bNumber of patients with data: 504 (placebo), 512 (ertugliflozin 5 mg), 502 (ertugliflozin 15 mg)
  4. cNumber of patients with data: 504 (placebo), 512 (ertugliflozin 5 mg), 501 (ertugliflozin 15 mg)